Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martine Piccart-Gebhart

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast CancerDimitrios Zardavas, Martine Piccart-Gebhart
Cancer Biology & Medicine|July 27, 2016
New generation of breast cancer clinical trials implementing molecular profilingDimitrios Zardavas, Martine Piccart-Gebhart
Future Oncology (London, England)|August 30, 2018
Mammaprint™: a comprehensive reviewMariana Brandão, Noam Pondé, Martine Piccart-Gebhart
Cancer Treatment Reviews|March 15, 2023
Optimizing treatment for HER2-positive HR-positive breast cancerVeronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart
Breast Care (Basel, Switzerland)|January 14, 2014
How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerAna Catarina Pinto, Evandro de Azambuja, Martine Piccart-Gebhart
BMJ Case Reports|April 22, 2014
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literatureMaha Mokrim, Philippe G Aftimos, Hassan Errihani, et al.
Nature Reviews. Clinical Oncology|August 2, 2017
HER2-positive breast cancer is lost in translation: time for patient-centered researchIsabelle Gingras, Géraldine Gebhart, Evandro de Azambuja, et al.
Molecular Oncology|April 23, 2009
The MINDACT trial: the first prospective clinical validation of a genomic toolFatima Cardoso, Martine Piccart-Gebhart, Laura Van't Veer, et al.
Targeted Oncology|May 7, 2009
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?Evandro de Azambuja, Philippe L Bedard, Thomas Suter, et al.
Breast (Edinburgh, Scotland)|October 1, 2013
Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapiesAna Catarina Pinto, Felipe Ades, Evandro de Azambuja, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast CancerDimitrios Zardavas, Martine Piccart-Gebhart
Cancer Biology & Medicine|July 27, 2016
New generation of breast cancer clinical trials implementing molecular profilingDimitrios Zardavas, Martine Piccart-Gebhart
Future Oncology (London, England)|August 30, 2018
Mammaprint™: a comprehensive reviewMariana Brandão, Noam Pondé, Martine Piccart-Gebhart
Cancer Treatment Reviews|March 15, 2023
Optimizing treatment for HER2-positive HR-positive breast cancerVeronique Debien, Evandro de Azambuja, Martine Piccart-Gebhart
Breast Care (Basel, Switzerland)|January 14, 2014
How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerAna Catarina Pinto, Evandro de Azambuja, Martine Piccart-Gebhart
BMJ Case Reports|April 22, 2014
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literatureMaha Mokrim, Philippe G Aftimos, Hassan Errihani, et al.
Nature Reviews. Clinical Oncology|August 2, 2017
HER2-positive breast cancer is lost in translation: time for patient-centered researchIsabelle Gingras, Géraldine Gebhart, Evandro de Azambuja, et al.
Molecular Oncology|April 23, 2009
The MINDACT trial: the first prospective clinical validation of a genomic toolFatima Cardoso, Martine Piccart-Gebhart, Laura Van't Veer, et al.
Targeted Oncology|May 7, 2009
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?Evandro de Azambuja, Philippe L Bedard, Thomas Suter, et al.
Breast (Edinburgh, Scotland)|October 1, 2013
Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapiesAna Catarina Pinto, Felipe Ades, Evandro de Azambuja, et al.
Pageof 8